Pershing Edward bought PVCT
October 10, 2026 · Form 4 insider transaction
Pershing Edward bought 22,609 shares of Provectus Biopharmaceuticals, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as option exercise and disclosed on an SEC Form 4, filed 3 days after the transaction.
Direction
Acquired (buy-side)
Shares
22,609
Price
$0.00
Total value
N/A
InsiderPershing Edward
Role—
SecuritySeries D-1 Convertible Preferred Stock
Transaction codeM: Option exercise
Transaction dateOctober 10, 2026
Filing dateOctober 13, 2026
Shares owned after2,998,534
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").; The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.